US Pulmonary Function Testing Systems Market

US Pulmonary Function Testing Systems Market Research Report: By Product Type (Spirometers, Peak Flow Meters, Gas Exchange Analyzers, Body Plethysmographs), By Application (Chronic Obstructive Pulmonary Disease, Asthma, Interstitial Lung Disease, Cystic Fibrosis), By End User (Hospitals, Diagnostic Laboratories, Home Care Settings, Research Institutions) and By Technology (Flow-Volume Measurement, Lung Volume Measurement, Gas Diffusion Measurement) - Growth & Industry Forecast 2025 To 2035
ID: MRFR/LS/11207-HCR 100 Pages Satyendra Maurya, Garvit Vyas Last Updated: September 15, 2026
US Pulmonary Function Testing Systems Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.99%
2024 Market Size$ 1,124.48 Million
2025 Market Size$ 1,169.35 Million
2035 Market Size$ 1,730.05 Million
Key Players
CareFusion
MediSoft
Schiller AG
Vyaire Medical
COSMED
NDD Medical Technologies
Trends
  • Technological Advancements
  • Increased Awareness of Respiratory Diseases
  • Regulatory Support and Funding Initiatives
Opportunities
  • Rising Geriatric Population
  • Growing Focus on Preventive Healthcare
  • Rising Prevalence of Respiratory Disorders
Request Free Sample

US Pulmonary Function Testing Systems Market Summary

As per Market Research Future analysis, the US pulmonary function-testing-systems market size was estimated at 1124.48 USD Million in 2024.. The US pulmonary function-testing-systems market is projected to grow from 1169.35 USD Million in 2025 to 1730.05 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 3.9% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The US pulmonary function-testing-systems market is experiencing robust growth driven by technological advancements and increasing awareness of respiratory diseases.

  • Technological advancements in pulmonary function testing equipment are enhancing diagnostic accuracy and efficiency.
  • The largest segment in the market is the hospital segment, while the home care segment is the fastest-growing.
  • Increased awareness of respiratory diseases is driving demand for pulmonary function testing across various healthcare settings.
  • Rising prevalence of respiratory disorders and growing focus on preventive healthcare are key market drivers.

Market Size & Forecast

2024 Market Size 1124.48 (USD Million)
2035 Market Size 1730.05 (USD Million)
CAGR (2025 - 2035) 3.99%

Major Players

CareFusion (US), MediSoft (DE), Schiller AG (CH), Vyaire Medical (US), COSMED (IT), NDD Medical Technologies (CH), Vitalograph (IE), Jaeger (DE)

US Pulmonary Function Testing Systems Market Drivers

Rising Geriatric Population

The aging population in the US is a critical driver for the pulmonary function-testing-systems market. As individuals age, the risk of developing respiratory diseases increases, necessitating regular monitoring of lung function. The US Census Bureau projects that by 2030, one in five Americans will be of retirement age, leading to a higher prevalence of age-related respiratory conditions. This demographic shift is prompting healthcare providers to invest in pulmonary function testing systems to cater to the needs of older adults. Consequently, the market is expected to grow as healthcare systems adapt to the increasing demand for effective respiratory disease management among the elderly.

Growing Focus on Preventive Healthcare

The shift towards preventive healthcare in the US is a significant driver for the pulmonary function-testing-systems market. Healthcare providers are increasingly emphasizing early detection and management of respiratory diseases to reduce long-term healthcare costs. This proactive approach encourages regular screening and monitoring of lung function, particularly among high-risk populations such as smokers and individuals with a family history of respiratory conditions. As a result, the demand for pulmonary function testing systems is likely to increase, as these tools are essential for identifying potential issues before they escalate. The market is projected to expand as healthcare systems adopt more preventive measures.

Rising Prevalence of Respiratory Disorders

The increasing incidence of respiratory disorders in the US is a primary driver for the pulmonary function-testing-systems market. Conditions such as asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease are becoming more prevalent, affecting millions of individuals. According to the CDC, approximately 25 million Americans have asthma, and COPD is projected to be the third leading cause of death by 2030. This growing patient population necessitates the use of advanced pulmonary function testing systems to facilitate accurate diagnosis and effective management of these diseases. As healthcare providers seek to improve patient outcomes, the demand for reliable and efficient testing systems is likely to rise, thereby propelling the market forward.

Technological Innovations in Testing Equipment

Technological advancements in pulmonary function-testing systems are significantly influencing the market landscape. Innovations such as portable spirometers, advanced software for data analysis, and integration with telehealth platforms are enhancing the capabilities of these systems. The introduction of mobile applications that allow patients to monitor their lung function at home is also gaining traction. These developments not only improve the accuracy of tests but also increase accessibility for patients. The market is expected to witness a compound annual growth rate (CAGR) of around 7% over the next few years, driven by these technological innovations that cater to both clinical and home settings.

Increased Investment in Healthcare Infrastructure

Investment in healthcare infrastructure in the US is positively impacting the pulmonary function-testing-systems market. Government initiatives and private sector funding are being directed towards enhancing healthcare facilities, particularly in underserved areas. This expansion includes the procurement of advanced pulmonary function testing equipment, which is crucial for accurate diagnosis and treatment of respiratory conditions. The US government has allocated substantial funds to improve healthcare access, which is expected to drive the demand for pulmonary function-testing systems. As more facilities are equipped with these systems, the market is likely to experience growth, reflecting the commitment to improving respiratory health outcomes.

Market Segment Insights

By Type: Spirometers (Largest) vs. Gas Exchange Analyzers (Fastest-Growing)

In the US pulmonary function-testing-systems market, Spirometers dominate the market share due to their established presence and critical role in diagnosing and managing respiratory conditions. They are widely used in both clinical and home settings, aiding in the detection of obstructive and restrictive lung diseases. Peak Flow Meters also maintain a significant share by assisting in asthma management, while Body Plethysmographs are favored for their comprehensive measurement of lung volume and airflow resistance. Gas Exchange Analyzers are the fastest-growing segment, fueled by an increasing focus on metabolic health and the rising prevalence of chronic respiratory diseases. The shift towards home care and telemedicine, coupled with innovative advancements in technology, is propelling market growth. Increased awareness of pulmonary conditions and the need for early diagnosis also serve as critical drivers for this segment, contributing to its rapid expansion.

Spirometers (Dominant) vs. Gas Exchange Analyzers (Emerging)

Spirometers remain the dominant player in the market, characterized by their accuracy, reliability, and ease of use, making them essential for routine pulmonary function testing. They help evaluate lung function and support various diagnoses, thereby maintaining a strong foothold in both hospital and outpatient settings. In contrast, Gas Exchange Analyzers are emerging with a focus on assessing lung function through gas exchange efficiency, reflecting an evolving trend towards personalized medicine. Their growing adoption in research and clinical environments, driven by technological improvements and enhanced functionalities, positions them as critical tools for improving patient outcomes and understanding complex respiratory conditions.

By Application: Chronic Obstructive Pulmonary Disease (Largest) vs. Asthma (Fastest-Growing)

In the US pulmonary function-testing-systems market, Chronic Obstructive Pulmonary Disease (COPD) represents the largest segment, significantly influencing market dynamics. This segment's dominance stems from the increasing prevalence of COPD and the extensive demand for accurate diagnostic and monitoring devices. In contrast, asthma has emerged as the fastest-growing segment, driven by rising awareness and enhanced healthcare initiatives aimed at early detection and management. The growth trend in the application segment is primarily driven by the rising incidence of respiratory diseases, particularly among the aging population. Innovations in pulmonary function testing technology and the introduction of user-friendly devices are propelling market expansion. Furthermore, increased investments in healthcare infrastructure contribute to the rapid adoption of these systems across hospitals and outpatient settings, ultimately enhancing patient care and outcomes.

Chronic Obstructive Pulmonary Disease (Dominant) vs. Asthma (Emerging)

Chronic Obstructive Pulmonary Disease (COPD) remains the dominant application in the US pulmonary function-testing-systems market, characterized by a high demand for precise diagnosis and ongoing monitoring of the condition. The robust utilization of spirometers and other diagnostic tools establishes COPD as a principal focus for clinicians. Meanwhile, asthma represents an emerging segment, benefiting from increasing public health initiatives and educational campaigns aimed at improving disease awareness. Both segments exhibit distinct characteristics: COPD requires long-term management solutions, while asthma’s variability in symptoms necessitates adaptable testing and treatment approaches, showcasing the diverse needs within the pulmonary health landscape.

By End User: Hospitals (Largest) vs. Home Care Settings (Fastest-Growing)

In the US pulmonary function-testing-systems market, hospitals represent the largest segment, commanding a significant portion of the market share due to their extensive patient base and advanced capabilities. Diagnostic laboratories follow closely, benefiting from their specialized services. Home care settings are emerging as a vital segment, driven by the increasing preference for remote patient monitoring and cost-effective care solutions. Research institutions contribute to the market primarily through clinical studies and innovations. The growth trends within this segment are primarily fueled by technological advancements and an increasing demand for efficient diagnostic tools. Hospitals continue to innovate, integrating advanced pulmonary function testing systems to enhance patient outcomes. Conversely, home care settings are rapidly growing as more patients prefer the convenience of at-home testing. The rising geriatric population and chronic respiratory conditions are key drivers propelling this segment forward.

Hospitals (Dominant) vs. Home Care Settings (Emerging)

Hospitals have established themselves as the dominant force in the US pulmonary function-testing-systems market, utilizing advanced technology and comprehensive resources to provide accurate testing and treatment. Their expansive infrastructure allows for complex diagnostics, catering to a diverse patient demographic. Conversely, home care settings are emerging as an attractive alternative, providing patients with the flexibility and comfort of receiving care in their own homes. This segment focuses on outpatient services and is supported by increased healthcare policies promoting home-based care. Both segments play crucial roles, with hospitals leading in volume and innovation, while home care settings are poised for significant growth driven by patient preference and technological advancements in at-home testing.

By Technology: Flow-Volume Measurement (Largest) vs. Gas Diffusion Measurement (Fastest-Growing)

In the US pulmonary function-testing-systems market, Flow-Volume Measurement holds the largest market share among the segment values, driven by its wide adoption in clinical settings for diagnosing various respiratory conditions. This segment benefits from established technology and reliability, allowing healthcare providers to effectively monitor patients' airflow and lung function. In contrast, Gas Diffusion Measurement, though smaller in market share, is rapidly gaining traction as clinicians seek comprehensive evaluations of gas exchange efficiency in the lungs, enhancing its appeal in specialized pulmonary assessments. Growth trends indicate an increasing emphasis on early detection and management of respiratory conditions, which fuels advancements in pulmonary function testing technologies. The move towards non-invasive testing methods and the integration of digital health solutions are significant drivers for both Flow-Volume and Gas Diffusion Measurements. Furthermore, rising healthcare expenditures and a growing aging population are expected to support sustained demand in these segments, particularly favoring the rapid expansion of Gas Diffusion Measurement technology in the coming years.

Technology: Flow-Volume Measurement (Dominant) vs. Gas Diffusion Measurement (Emerging)

Flow-Volume Measurement is characterized by its established role in routine pulmonary assessments, utilizing easy-to-use devices that allow for quick and accurate evaluation of airflow rates. This segment leads in market dominance due to its reliability, cost-effectiveness, and the support of regulatory standards, making it the preferred choice for many healthcare facilities. On the other hand, Gas Diffusion Measurement represents an emerging technology with a focus on assessing how well oxygen and carbon dioxide are exchanged in the lungs. This segment, although smaller, is seeing increased interest due to enhanced capabilities in diagnosing conditions like pulmonary fibrosis and emphysema, thereby positioning it for significant growth as clinical needs evolve.

Get more detailed insights about US Pulmonary Function Testing Systems Market
Request Free Sample

Key Players and Competitive Insights

The pulmonary function-testing-systems market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for respiratory diagnostics. Key players such as CareFusion (US), Vyaire Medical (US), and NDD Medical Technologies (CH) are strategically positioned to leverage innovation and expand their market presence. CareFusion (US) focuses on enhancing its product portfolio through continuous research and development, while Vyaire Medical (US) emphasizes partnerships with healthcare providers to improve patient outcomes. NDD Medical Technologies (CH) appears to be concentrating on digital transformation, integrating advanced software solutions into its testing systems, which collectively shapes a competitive environment that prioritizes innovation and customer-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure is moderately fragmented, with several players competing for market share. This fragmentation allows for diverse offerings, yet the influence of major companies remains significant, as they set benchmarks for quality and technological advancement.

In October Vyaire Medical (US) announced a strategic partnership with a leading telehealth provider to integrate remote pulmonary function testing into their platform. This move is likely to enhance accessibility for patients, particularly in rural areas, and reflects a growing trend towards telemedicine in respiratory care. By aligning with telehealth services, Vyaire Medical (US) positions itself at the forefront of a rapidly evolving healthcare landscape, potentially increasing its market share.

In September CareFusion (US) launched a new line of portable spirometers designed for home use, which could significantly impact patient compliance and monitoring. This innovation not only addresses the need for convenient testing solutions but also aligns with the increasing emphasis on patient-centered care. The introduction of such products may enhance CareFusion's competitive edge by catering to the growing demand for at-home healthcare solutions.

In August NDD Medical Technologies (CH) unveiled an advanced software update for its pulmonary function testing systems, incorporating artificial intelligence to improve diagnostic accuracy. This strategic enhancement indicates a commitment to leveraging technology for better patient outcomes, potentially setting a new standard in the industry. The integration of AI could lead to more precise assessments, thereby attracting healthcare providers seeking reliable diagnostic tools.

As of November the competitive trends in the pulmonary function-testing-systems market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming pivotal, as companies collaborate to enhance their technological capabilities and expand their service offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, suggesting a transformative shift in how companies position themselves in the market.

Key Companies in the US Pulmonary Function Testing Systems Market include

Recent Industry Developments

In the US Pulmonary Function Testing Systems Market, notable developments include recent technological innovations and growing interest in home healthcare solutions. Companies such as Omron Healthcare and Vitalograph are increasingly focusing on developing portable and user-friendly devices to facilitate remote patient monitoring amid the COVID-19 pandemic's ongoing impact. Smiths Medical and CareFusion have also introduced updates to existing systems to enhance accuracy and compliance with FDA regulations.

In terms of mergers and acquisitions, Medtronic announced in September 2023 a strategic acquisition of a leading digital health company that specializes in remote pulmonary monitoring. Additionally, Vyaire Medical has partnered with various healthcare providers to expand its product offerings and improve accessibility to pulmonary function tests for patients nationwide.

The market has been experiencing growth, as the American Lung Association reported increased funding and research initiatives aimed at improving respiratory health, which has positively influenced revenue potential for companies like Natus Medical and MGC Diagnostics. Overall, the US market is adapting to new healthcare demands, prioritizing innovation, accessibility, and improved pulmonary health outcomes.

Future Outlook

US Pulmonary Function Testing Systems Market Future Outlook

The Pulmonary Function Testing Systems Market is projected to grow at a 3.99% CAGR from 2025 to 2035, driven by technological advancements, increasing respiratory diseases, and rising healthcare expenditure.

New opportunities lie in:

  • Development of portable pulmonary function testing devices for home use.
  • Integration of AI-driven analytics for enhanced diagnostic accuracy.
  • Expansion of telehealth services for remote pulmonary function assessments.

By 2035, the market is expected to achieve robust growth, reflecting advancements and increased demand.

Market Segmentation

US Pulmonary Function Testing Systems Market Type Outlook

  • Spirometers
  • Peak Flow Meters
  • Gas Exchange Analyzers
  • Body Plethysmographs

US Pulmonary Function Testing Systems Market End User Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Home Care Settings
  • Research Institutions

US Pulmonary Function Testing Systems Market Technology Outlook

  • Flow-Volume Measurement
  • Lung Volume Measurement
  • Gas Diffusion Measurement

US Pulmonary Function Testing Systems Market Application Outlook

  • Chronic Obstructive Pulmonary Disease
  • Asthma
  • Interstitial Lung Disease
  • Cystic Fibrosis

Report Scope

MARKET SIZE 2024 1124.48(USD Million)
MARKET SIZE 2025 1169.35(USD Million)
MARKET SIZE 2035 1730.05(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 3.99% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled CareFusion (US), MediSoft (DE), Schiller AG (CH), Vyaire Medical (US), COSMED (IT), NDD Medical Technologies (CH), Vitalograph (IE), Jaeger (DE)
Segments Covered Type, Application, End User, Technology
Key Market Opportunities Integration of artificial intelligence in pulmonary function-testing-systems enhances diagnostic accuracy and patient management.
Key Market Dynamics Technological advancements and regulatory changes drive innovation in the pulmonary function-testing-systems market.
Countries Covered US

Frequently Asked Questions

What is the current valuation of the US pulmonary function-testing-systems market?

The market valuation was $1124.48 Million in 2024.

What is the projected market valuation for the US pulmonary function-testing-systems market by 2035?

The projected valuation for 2035 is $1730.05 Million.

What is the expected CAGR for the US pulmonary function-testing-systems market during the forecast period 2025 - 2035?

The expected CAGR during this period is 3.99%.

Which companies are considered key players in the US pulmonary function-testing-systems market?

Key players include CareFusion (US), MediSoft (DE), Schiller AG (CH), and Vyaire Medical (US).

What are the main segments of the US pulmonary function-testing-systems market?

The main segments include Type, Application, End User, and Technology.

What was the market size for spirometers in 2024?

The market size for spirometers was between $450.0 Million and $700.0 Million.

How much is the market for chronic obstructive pulmonary disease applications projected to be by 2035?

The market for chronic obstructive pulmonary disease applications is projected to be between $450.0 Million and $700.0 Million.

What is the expected market size for diagnostic laboratories as end users in 2024?

The expected market size for diagnostic laboratories was between $300.0 Million and $450.0 Million.

What are the projected values for gas diffusion measurement technology by 2035?

The projected values for gas diffusion measurement technology are between $324.48 Million and $530.05 Million.

How does the market for body plethysmographs compare to other types in 2024?

The market for body plethysmographs was between $224.48 Million and $330.05 Million, indicating a competitive position among other types.

Author
Author Author Profile Satyendra Maurya LinkedIn Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author Co-Author Profile Garvit Vyas LinkedIn Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Get In Touch
Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.